Equillium’s pipeline consists of the following novel first-in-class immunomodulatory assets.

EQ504: an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and pouchitis or inhaled formulations for the treatment of inflammatory lung diseases.

EQ302: an selective bi-specific cytokine inhibitor targeting IL-15 and IL-21, two cytokines central to T and B cell activity that exhibit biological synergy driving aggressive inflammatory responses in a number of gastrointestinal and skin diseases.